These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 10959689

  • 1. Local and systemic effects of intra-arterial desmopressin in healthy volunteers and patients with type 3 von Willebrand disease. Role of interleukin-6.
    Newby DE, Stewart A, Witherow FN, Grieve S, Dawson P, Fox KA, Webb DJ, Ludlam CA.
    Thromb Haemost; 2000 Aug; 84(2):195-203. PubMed ID: 10959689
    [Abstract] [Full Text] [Related]

  • 2. Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease.
    Wieczorek I, Ludlam CA, MacGregor IR.
    Blood Coagul Fibrinolysis; 1994 Jun; 5(3):329-34. PubMed ID: 8075304
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.
    Castaman G, Federici AB, Bernardi M, Moroni B, Bertoncello K, Rodeghiero F.
    J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565
    [Abstract] [Full Text] [Related]

  • 5. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ, van de Velde A, van Vliet HH, van der Planken M, Schroyens W, Berneman Z.
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
    Brink HS, Derkx FH, Boomsma F, Brommer EJ, Schalekamp MA.
    Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
    [Abstract] [Full Text] [Related]

  • 8. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
    Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Knöbl P.
    Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
    [Abstract] [Full Text] [Related]

  • 9. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S, Mezzasoma AM, Leone M, Gresele P.
    Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH, Kappers-Klunne MC, Leebeek FW, Michiels JJ.
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [Abstract] [Full Text] [Related]

  • 12. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z.
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [Abstract] [Full Text] [Related]

  • 13. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
    Robinson SD, Dawson P, Ludlam CA, Boon NA, Newby DE.
    Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
    [Abstract] [Full Text] [Related]

  • 14. Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm.
    Wall U, Jern S, Tengborn L, Jern C.
    Blood; 1998 Jan 15; 91(2):529-37. PubMed ID: 9427706
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A, Berneman Z, Schroyens W, Michiels JJ.
    Acta Haematol; 2009 Jan 15; 121(2-3):128-38. PubMed ID: 19506359
    [Abstract] [Full Text] [Related]

  • 20. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW, Helmy A, Ludlam C, Webb DJ, Hayes PC, Newby DC.
    Thromb Res; 2008 Jan 15; 121(5):675-80. PubMed ID: 17870147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.